The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease with considerable impact on patients and carers as the disease progresses. Currently few treatments are available. We aimed to evaluate the clinical and cost-effectiveness of available treatments for IPF. METHODS: Systematic reviews of clinical effectiveness, quality of life and cost effectiveness were undertaken. Eleven bibliographic databases were searched from inception to July 2013 and studies were assessed for eligibility against a set of pre-defined criteria. Two reviewers screened references, extracted data from included studies and appraised their quality. An advisory group was consulted about the choice of interventions. A narrative review was undertaken and where feasible fixed effect and random effects meta-analysis were undertaken including a network meta-analysis (NMA). A decision-analytic Markov model was developed to estimate cost-effectiveness of pharmacological treatments for IPF. Following best practice recommendations, the model perspective was of the national health service and personal social services, a discount rate of 3.5% for costs and health benefits was applied and outcomes were expressed as cost per quality adjusted life-year gained. Parameter values were obtained from the NMA and systematic reviews. Sensitivity analyses were undertaken. RESULTS: Fourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine, three N-acetylcysteine [NAC] (alone or in combination), four pirfenidone, one nintedanib, one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management programme. Study quality was generally good. Evidence suggests that some effective treatments are available. In NMA only nintedanib and pirfenidone show statistically significant improvements. The model results show increased survival for five pharmacological treatments (NAC triple therapy, inhaled NAC, nintedanib, pirfenidone, and sildenafil) compared with best supportive care, at increased cost. Only inhaled NAC was cost-effective at current willingness to pay thresholds but it may not be clinically effective. CONCLUSIONS: Few interventions have any statistically significant effect and the cost-effectiveness of treatments is uncertain. A lack of studies on palliative care approaches was identified and there is a need for further research into pulmonary rehabilitation and thalidomide in particular. A well conducted RCT on inhaled NAC therapy should also be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600 · cited 1×
“A NMA focusing on pharmacological treatments for IPF and assessing forced vital capacity (FVC) endpoints was undertaken [12].”
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“The prevalence of IPF is increasing, although the cause of this increase is uncertain, [3,4] and with a poor prognosis (estimated mean survival of between 2–5 years) IPF has become an area of focus with recent UK national guidelines on the diagnosis and management of IPF published, [5] and international consensus guid…”
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964 · cited 3×
“2012 [20] Mean Age: 68 years Primary outcomes: absolute change in FVC at 48 weeks Unclear risk”
Demystifying trial networks and network meta-analysis
Mills, E. J., Thorlund, K., & Ioannidis, J. P. A. (2013) · BMJ · doi:10.1136/bmj.f2914 · Cited by 742
A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634 · cited 17×
“Systematic reviews were undertaken of clinical effectiveness (including only randomised controlled trials [RCTs] and controlled clinical trials [CCTs]), economic evaluations and health related quality of life (HRQoL) studies.”
Influential
Cited by
Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O. (2017) · ERJ Open Research · doi:10.1183/23120541.00074-2016 · Cited by 139
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine · doi:10.1186/s12916-016-0558-x · Cited by 101
“), the analysis relied on standardized mean differences, which limit application in decision-making [8].”
BackgroundMethodInfluentialBouros, D., Daniil, Z., Papakosta, D., Antoniou, K. M., Markopoulou, K., Kolilekas, L., Konstantopoulos, G., Papiris, S., & on behalf of the INDULGE IPF Study Group (2018) · Respiration · doi:10.1159/000487244 · Cited by 7
Metadata
- Authors
- Loveman, E., Copley, V. R., Colquitt, J. L., Scott, D. A., Clegg, A. J., Jones, J., O’Reilly, K. M., Singh, S., Bausewein, C., & Wells, A.
- Venue
- BMC Pharmacology and Toxicology
- Published
- 2014-11-19
- Volume
- 15
- Issue
- 1
- Pages
- 63-63
- ISSN
- 2050-6511 (ISSN-L)
- OpenAlex
- W2079081546
- Cited by
- 52
- References
- 7
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. https://app.cochat.ai/papers/10.1186/2050-6511-15-63
- The paper
- Loveman, E., Copley, V. R., Colquitt, J. L., Scott, D. A., Clegg, A. J., Jones, J., O’Reilly, K. M., Singh, S., Bausewein, C., & Wells, A. (2014). The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-15-63
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.